Purchase of a Multi-Angle Light Scattering System with Integrated Size Exclusion Chromatography

 描述(由申请人提供)：建议的集成尺寸排除层析的多角度光散射仪(SEC-MALS)。该仪器将支持五个主要用户，他们都从事生物医学研究，其中四个得到了NIH的支持。具体项目集中在以下几个方面：确定结构眼晶状体蛋白的结构聚集倾向和寡聚化状态，了解蛋白质折叠过程中形成的中间产物，表征膜蛋白与膜和蛋白质结合伙伴的相互作用，设计用于医疗诊断的新型仿生材料和纳米颗粒。这些项目中研究的大分子与许多疾病有关，如白内障、衣原体感染、胃溃疡和癌症。此外，三名初级用户，他们都是初级教员，拥有有前途的研究计划，将有机会使用该仪器，促进他们的研究并加强他们未来的建议。利用拟议的仪器获得的生物物理信息和理解可以为设计新的、创新的治疗方法提供基础。拟议系统的最大影响来自这样一个事实，即UCI目前没有可供用户使用的现代、功能强大的MALS仪器。因此，需要这项技术的研究人员必须依赖外部合作者和公司，这减缓了研究进展的步伐，并严重限制了可以收集的数据量。主要用户和次要用户都将受益于新仪器的DLS和SLS功能，使我们能够在结构生物学、仿生材料和生物物理化学领域产生重大影响。收购拟议的SEC-MALS仪器对于缓解UCI目前和未来的表征需求以及UCI继续进行高影响力的生物医学研究至关重要。

 DESCRIPTION (provided by applicant): The proposed multi-angle light scattering instrument with integrated size exclusion chromatography (SEC-MALS). The instrument will support five major users, all of whom are engaged in biomedical research, and four of whom are supported by NIH. Specific projects are focused on the following: determining the structural aggregation propensity and oligomerization state of structural eye lens proteins, understanding intermediates formed during protein folding, characterizing the interactions of membrane proteins with both membranes and protein binding partners, designing novel biomimetic materials and nanoparticles for medical diagnosis. The macromolecules studied in these projects are associated with numerous diseases, such as cataract, chlamydia, gastric ulcers and cancer. Additionally, three minor users, all of whom are junior faculty with promising research programs, will have the opportunity to use this instrument, advancing their research and strengthening their future proposals. The biophysical information and understanding gained with the proposed instrument could provide the basis for designing new, innovative treatments. The biggest impact of the proposed system derives from the fact that there is currently no modern, functional MALS instrument available for users at UCI. As a result, researchers who need this technology must rely on external collaborators and companies, slowing down the pace of research progress and severely curtailing the amount of data that can be collected. The Major and Minor Users will all benefit from the DLS and SLS capabilities of the new instrument, enabling us to make a major impact on the fields of structural biology, biomimetic materials, and biophysical chemistry. The acquisition of the proposed SEC-MALS instrument is essential to alleviating UCI's current and future characterization demands and for UCI to continue doing high-impact biomedical research.